THE HEMATOPOIETIC CELL TRANSPLANTATION-SPECIFIC COMORBIDITY INDEX (HCT-CI) PREDICTS SURVIVAL AND NON-RELAPSE MORTALITY IN LYMPHOMA AND MYELOMA PATIENTS RECEIVING RIC ALLOGRAFT